Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai Henlius Biotech, Inc.
上海復宏漢霖生物技術股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2696)

PROPOSED APPOINTMENT OF DIRECTORS OF THE FOURTH SESSION OF THE BOARD PROPOSED APPOINTMENT OF SHAREHOLDER REPRESENTATIVE SUPERVISORS OF THE FOURTH SESSION OF THE BOARD OF SUPERVISORS AND APPOINTMENT OF EMPLOYEE REPRESENTATIVE SUPERVISOR

PROPOSED RE-APPOINTMENT AND APPOINTMENT OF DIRECTORS OF THE FOURTH SESSION OF THE BOARD

The term of the third session of the Board has expired recently, and each Director shall continue to perform his/her duties as Director until the conclusion of the EGM at which the fourth session of the Board will be elected.

The Board proposes that the fourth session of the Board be comprised of eleven Directors, including one executive Director, six non-executive Directors and four independent non-executive Directors. The Board has considered and approved the re-appointment and appointment of the following candidates for Directors of the fourth session of the Board:

The Board proposes (i) the re-appointment of Dr. Jun Zhu, being the current executive Director, as the executive Director of the fourth session of the Board; (ii) the re-appointment of Mr. Wenjie Zhang, Mr. Qiyu Chen, Ms. Xiaohui Guan and Dr. Xingli Wang, being the current non-executive Directors, as the non-executive Directors of the fourth session of the Board; (iii) the re-appointment of Mr. Tak Young So, Dr. Lik Yuen Chan and Dr. Ruilin Song, being the current independent non-executive Directors, as the independent non-executive Directors of the fourth session of the Board; (iv) the appointment of Mr. Yuqing Chen and Dr. Yi Liu as the non-executive Directors of the fourth session of the Board; and (v) the appointment of Mr. Yihao Zhang as an independent non-executive Director of the fourth session of the Board.

PROPOSED RE-APPOINTMENT OF SHAREHOLDER REPRESENTATIVE SUPERVISORS OF THE FOURTH SESSION OF THE BOARD OF SUPERVISORS AND RE-APPOINTMENT OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The term of the third session of the Board of Supervisors has expired recently, and the Board of Supervisors proposes that the fourth session of the Board of Supervisors be comprised of three Supervisors, including two Shareholder representative Supervisors elected by Shareholders and one employee representative Supervisor elected at the employee representative meeting of the Company.

The Board of Supervisors proposes the re-appointment of Ms. Rongli Feng and Mr. Deli Kong, being the current Shareholder representative Supervisors, as the Shareholder representative Supervisors of the fourth session of the Board of Supervisors. Ms. Rongli Feng and Mr. Deli Kong shall continue to perform their duties as Shareholder representative Supervisor until the conclusion of the EGM at which the fourth session of the Board of Supervisors will be elected.

Mr. Zhiyong Liu, being the current employee representative Supervisor, has been re-appointed as the employee representative Supervisor of the fourth session of the Board of Supervisors at the employee representative meeting of the Company held on 8 August 2025.

GENERAL

The Company intends to propose relevant resolutions at the EGM for seeking Shareholders' approval of (i) the proposed re-appointment and appointment of Directors of the fourth session of the Board; and (ii) the proposed re-appointment of Shareholder representative Supervisors of the fourth session of the Board of Supervisors. A circular containing, among other things, details of (i) the resolutions of the proposed re-appointment and appointment of Directors of the fourth session of the Board; (ii) the resolutions of the proposed re-appointment of Shareholder representative Supervisors of the fourth session of the Board of Supervisors; and (iii) the notice of the EGM, will be despatched to the Shareholders in accordance with the Listing Rules and the Articles of Association.

PROPOSED RE-APPOINTMENT AND APPOINTMENT OF DIRECTORS OF THE FOURTH SESSION OF THE BOARD

The Board currently comprises eleven Directors, including one executive Director, six non-executive Directors, and four independent non-executive Directors. The term of the third session of the Board has expired recently, and each Director shall continue to perform his/her duties as Director until the conclusion of the EGM at which the fourth session of the Board will be elected.

The Board proposes that the fourth session of the Board be comprised of eleven Directors, including one executive Director, six non-executive Directors and four independent non-executive Directors. The Board has considered and approved the re-appointment and appointment of the following candidates for Directors of the fourth session of the Board:

The Board proposes (i) the re-appointment of Dr. Jun Zhu, being the current executive Director, as the executive Director of the fourth session of the Board; (ii) the re-appointment of Mr. Wenjie Zhang, Mr. Qiyu Chen, Ms. Xiaohui Guan and Dr. Xingli Wang, being the current non-executive Directors, as the non-executive Directors of the fourth session of the Board; (iii) the re-appointment of Mr. Tak Young So, Dr. Lik Yuen Chan and Dr. Ruilin Song, being the current independent non-executive Directors, as the independent non-executive Directors of the fourth session of the Board; (iv) the appointment of Mr. Yuqing Chen and Dr. Yi Liu as the non-executive Directors of the fourth session of the Board; and (v) the appointment of Mr. Yihao Zhang as an independent non-executive Director of the fourth session of the Board.

The above candidates for Directors meet the qualification requirements to serve as Directors as stipulated in relevant PRC laws, regulations, the Articles of Association and the Listing Rules, and the Board agreed to submit the above list of candidates for Directors to be considered and approved at the EGM by way of ordinary resolutions. The EGM will elect one executive Director, six non-executive Directors, and four independent non-executive Directors, and these eleven Directors will comprise the fourth session of the Board.

In accordance with the requirements of relevant PRC laws, regulations and the Articles of Association, the candidates for Directors of the fourth session of the Board are subject to the consideration and approval by the Shareholders at the EGM. The term of office of candidates for executive Director, non-executive Directors and independent non-executive Directors will take effect from the date of approval at the EGM and will end upon the expiry of the term of the fourth session of the Board.

The biographical details of the candidates for the Directors of the fourth session of the Board are set out in Appendix I to this announcement.

Mr. Yifang Wu, Mr. Deyong Wen and Dr. Guoping Zhao will retire from their office as a non-executive Director, a non-executive Director and an independent non-executive Director, and the retirement will be effective from the date of the election of the fourth session of the Board at the EGM. Mr. Yifang Wu, Mr. Deyong Wen and Dr. Guoping Zhao confirmed that they have no disagreement with the Board and the Company and there is no other matter in relation to their Retirement that needs to be brought to the attention of the Shareholders. The Board would like to take this opportunity to express its sincere gratitude to Mr. Yifang Wu, Mr. Deyong Wen and Dr. Guoping Zhao for their contributions to the Company during their tenure.

PROPOSED RE-APPOINTMENT OF SHAREHOLDER REPRESENTATIVE SUPERVISORS OF THE FOURTH SESSION OF THE BOARD OF SUPERVISORS AND RE-APPOINTMENT OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The Board of Supervisors currently comprises of three Supervisors, including two Shareholder representative Supervisors and one employee representative Supervisor. The term of the third session of the Board of Supervisors has expired recently, and the Board of Supervisors proposes that the fourth session of the Board of Supervisors be comprised of three Supervisors, including two Shareholder representative Supervisors elected by Shareholders and one employee representative Supervisor elected at the employee representative meeting of the Company.

(1) Proposed Re-appointment of Shareholder Representative Supervisors of the Fourth Session of the Board of Supervisors

The Board of Supervisors proposes the re-appointment of Ms. Rongli Feng and Mr. Deli Kong, being the current Shareholder representative Supervisors, as the Shareholder representative Supervisors of the fourth session of the Board of Supervisors. Ms. Rongli Feng and Mr. Deli Kong shall continue to perform their duties as Shareholder representative Supervisor until the conclusion of the EGM at which the fourth session of the Board of Supervisors will be elected.

The above candidates for Shareholder representative Supervisors meet the qualification requirements to serve as Supervisors as stipulated in relevant PRC laws, regulations and the Articles of Association, and the Board of Supervisors agreed to submit the above candidates for Shareholder representative Supervisors to be considered and approved at the EGM by way of ordinary resolutions.

The term of office of Ms. Rongli Feng and Mr. Deli Kong will take effect from the date of approval at the EGM and will end upon the expiry of the term of the fourth session of the Board of Supervisors.

The biographical details of the candidates for Shareholder representative Supervisors of the fourth session of the Board of Supervisors are set out in Appendix II to this announcement.

(2) Re-appointment of Employee Representative Supervisor of the Fourth Session of the Board of Supervisors

Mr. Zhiyong Liu ("**Mr. Liu**"), has been appointed as the employee representative Supervisor of the fourth session of the Board of Supervisors at the employee representative meeting of the Company held on 8 August 2025. Mr. Liu's term of office shall commence from the date of election until the expiry date of the fourth session of the Board of Supervisors (or the term of office shall expire at the conclusion of the employee representative meeting at which a new session of the employee representative Supervisor will be elected). Mr. Liu, together with the Shareholder representative Supervisors to be elected at the EGM, will constitute the fourth session of the Board of Supervisors. The biographical details of Mr. Liu are set out in Appendix III to this announcement.

GENERAL

The Company intends to propose relevant resolutions at the EGM for seeking Shareholders' approval of (i) the proposed re-appointment and appointment of Directors of the fourth session of the Board; and (ii) the proposed re-appointment of Shareholder representative Supervisors of the fourth session of the Board of Supervisors.

The resolutions of the proposed re-appointment and appointment of Directors of the fourth session of the Board and the resolutions of the proposed re-appointment of Shareholder representative Supervisors of the fourth session of the Board of Supervisors will be considered and approved by way of ordinary resolutions at the EGM.

A circular containing, among other things, details of (i) the resolutions of the proposed re-appointment and appointment of Directors of the fourth session of the Board; (ii) the resolutions of the proposed re-appointment of Shareholder representative Supervisors of the fourth session of the Board of Supervisors; and (iii) the notice of the EGM, will be despatched to the Shareholders in accordance with the Listing Rules and the Articles of Association.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms have the following meanings:

"Articles of Association"	the articles of association of the Company currently in force, as amended, modified or otherwise supplemented from time to time
"Board"	the board of Directors
"Board of Supervisors"	the board of Supervisors
"Company"	Shanghai Henlius Biotech, Inc., a joint stock company established in the People's Republic of China with limited liability, the H Shares of which are listed and traded on the Main Board of the Stock Exchange (stock code: 2696)
"Director(s)"	the director(s) of the Company

"EGM"	the extraordinary general meeting of the Company to be held, or any adjournment thereof, to consider and, if appropriate, to approve, among others, the proposed re-appointment and appointment of Directors of the fourth session of the Board; and the proposed re-appointment of shareholder representative Supervisors of the fourth session of the Board of Supervisors
"Group"	the Company and its subsidiaries
"H Share(s)"	overseas-listed foreign shares in the issued share capital of the Company with a nominal value of RMB1.00 each, which are listed on the Main Board of the Stock Exchange and traded in HK dollars
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange as amended from time to time
"PRC" or "Mainland"	the People's Republic of China, which for the purpose of this announcement only, excludes Hong Kong, Macau and Taiwan regions of China
"RMB"	Renminbi, the lawful currency of the PRC
"SFO"	Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong)
"Share(s)"	the domestic share(s), the unlisted foreign share(s) and/or H Share(s) with nominal value of RMB1.00 each in the issued share capital of the Company
"Shareholder(s)"	holder(s) of Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary(ies)"	has the meaning ascribed thereto under the Listing Rules
"Supervisor(s)"	the supervisor(s) of the Company

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 8 August 2025

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and non-executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.

The biographical details of the candidates for Directors are set out as below:

Dr. Jun Zhu (朱俊), aged 47, has served as the chief executive officer of the Company since July 2023 and has served as an executive Director of the Company since August 2023. Dr. Zhu joined the Group in January 2021 and has been the senior vice president and chief medical officer of Shanghai Henlius Biopharmaceutical Co., Ltd.* (上海復宏漢霖生物製藥有限公司) ("**Henlius Biopharmaceutical**"), and the senior vice president and chief medical officer, the president and chief financial officer of the Company. Dr. Zhu holds directorship and managerial positions in certain other subsidiaries of the Company.

Prior to joining the Company, Dr. Zhu served as the internal medicine physician in Huashan Hospital affiliated to Fudan University in Shanghai from July 2001 to October 2003; the project manager of IQVIA Holdings Inc. from August 2003 to June 2005; the general manager (Greater China) of Omnicare Clinical Research Inc. from March 2008 to July 2012; the global vice-president of IQVIA Holdings Inc. from August 2012 to January 2017; and the founder and chief executive officer of Shanghai PPC Biopharmaceutical Technology Co., Ltd.* (上海百利佳生醫藥科技有限公司) from February 2018 to August 2020.

Dr. Zhu obtained a bachelor's degree in clinical medicine from Fudan University (復旦大學) in the PRC in July 2001, an EMBA degree from Cheung Kong Graduate School of Business (長江商學院) in the PRC in September 2018, and a doctoral degree in health management from University of Montpellier in France in June 2024.

Dr. Zhu will not receive additional remuneration from the Company for serving as an executive Director.

As at the date of this announcement, Dr. Zhu holds 750,000 share options and 750,000 restricted share units (RSUs) granted under the Share Option Scheme and RSU Scheme of the Company. In addition, Dr. Zhu indirectly holds 50,000 shares of the Company through Dr. JZ Limited, which is under his control.

Mr. Wenjie Zhang, aged 58, has served as an executive Director of the Company from November 2020 to March 2025, has been a non-executive Director since March 2025, and has been the chairman of the Board since November 2021. Mr. Zhang joined the Company in March 2019 and has been the senior vice president and chief commercial operation officer, president and chief executive officer of the Company. Mr. Zhang serves as a director in certain subsidiaries of the Company. Mr. Zhang served as an executive president of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("**Fosun Pharma**", Shanghai Stock Exchange stock code: 600196, Stock Exchange stock code: 02196) from July 2023 to June 2025, has been a co-president of Fosun Pharma since June 2025 and has been a non-executive director of Gland Pharma Limited ("**Gland Pharma**", stock code of The Bombay Stock Exchange and The National Stock Exchange of India: GLAND) since August 2024.

Prior to joining Fosun Pharma and its subsidiaries ("**Fosun Pharma Group**"), Mr. Zhang served as the assistant engineer of research and development of Jinan Corbère Bioengineering Co., Ltd.* (濟南科貝爾生物工程有限公司) from July 1990 to December 1991, and the China sales representative of Sino-American Shanghai Squibb Pharmaceuticals Co., Ltd.* (中美上海施貴寶製藥有限公司) from January 1992 to August 1994. From May 1997 to December 2010, he worked at Bayer Group (stock code: BAYGn), a company listed on Frankfurt Stock Exchange of Germany, and successively served as the product manager of US Marketing Division at Bayer Pharmaceutical's US subsidiary, business development manager and deputy director of global marketing from May 1997 to November 2004, head of business development at Bayer Healthcare's Asia Pacific headquarters from November 2004 to August 2006, the head of Oncology and Specialty Medicine Business at Bayer Schering Pharma China from August 2006 to December 2010, and the head of Oncology and Specialty Medicine Business in Asia Pacific in 2010. He also served as vice president of Tumor Business Department II of Shanghai Roche Pharmaceutical Co., Ltd.* (上海羅氏製藥有限公司) from December 2010 to April 2014. From September 2014 to March 2019, he also worked at Amgen Inc. ("**Amgen**", NASDAQ Stock Exchange stock code: AMGN), and served as the executive director of Japan and Asia Pacific of Amgen from September 2014 to May 2015 and the general manager of Amgen Biopharmaceutical (Shanghai) Co., Ltd.* (安進生物醫藥(上海)有限公司) from May 2015 to March 2019.

Mr. Zhang obtained a bachelor's degree in science in microbiology from Shandong University in the PRC in July 1990, and a master's degree in business administration from Yale University in the United States in May 1998.

Mr. Zhang will not receive any remuneration from the Company for serving as a non-executive Director.

Mr. Qiyu Chen (陳啟宇), aged 53, has been a non-executive Director of the Company since February 2010 and served as the chairman of the Board from December 2018 to November 2021. Mr. Chen currently serves as the chairman of Shanghai Fosun High Technology (Group) Co., Ltd., an executive director and the co-chief executive officer of Fosun International Limited ("**Fosun International**", Stock Exchange stock code: 00656), a non-executive director and a vice chairman of Sinopharm Group Co. Ltd. ("**Sinopharm**", Stock Exchange stock code: 01099). Mr. Chen joined Fosun Pharma Group in April 1994, who successively served as a secretary to the board, general manager, vice chairman, executive director, chairman and other positions of Fosun Pharma from April 1994 to October 2020, and served as a non-executive director of Fosun Pharma since October 2020. Mr. Chen previously served as a non-executive director of Gland Pharma and a director of Beijing Sanyuan Foods Co., Ltd.* (北京三元食品股份有限公司) (Shanghai Stock Exchange stock code: 600429). In addition, Mr. Chen holds directorships in various companies invested by Fosun International and its affiliated companies.

Prior to joining Fosun Pharma Group, Mr. Chen worked at Shanghai RAAS Blood Products Co., Ltd.* (上海萊士血製品有限公司) (currently known as Shanghai RAAS Blood Products Co., Ltd.* (上海萊士血液製品股份有限公司) (Shenzhen Stock Exchange stock code: 002252)) from July 1993 to March 1994. Mr. Chen has been the chairman of China Medical Pharmaceutical Material Association (中國醫藥物資協會), a vice president of China Pharmaceutical Innovation and Research Development Association (中國醫藥創新促進會), the honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association (上海市生物醫藥行業協會), and a member of the 13th Shanghai Standing Committee of the Chinese People's Political Consultative Conference.

Mr. Chen obtained a bachelor's degree in genetics from Fudan University (復旦大學) in the PRC in July 1993 and a master's degree of business administration from China Europe International Business School (中歐國際工商學院) in the PRC in September 2005.

Mr. Chen will not receive any remuneration from the Company for serving as a non-executive Director.

Mr. Yuqing Chen (陳玉卿), aged 49, is currently an executive director and the chairman of the board of directors of Fosun Pharma, a senior vice president of Fosun International, and a non-executive director of Sinopharm. Mr. Chen joined Fosun Pharma Group in January 2010 and has been a deputy supervisor of the human resources department, a deputy general manager of the human resources department, the general manager of the human resources department, an assistant to the president, the general manager of the human resources department, a vice president, a senior vice president, the co-president and chief executive officer of Fosun Pharma; the chairman of the board of directors of Shanghai Fosun Health Technology (Group) Co., Ltd.*(上海復星健康科技(集團)有限公司), a subsidiary of Fosun Pharma, from August 2020 to May 2021 and from October 2022 to present; and a non-executive Director of Fosun Pharma from September 2024 to April 2025, and has served as an executive Director and the chairman of the Board of Fosun Pharma from April 2025. In addition, Mr. Chen holds directorship and managerial positions in certain subsidiaries of Fosun Pharma.

Prior to joining Fosun Pharma Group, Mr. Chen served as a teacher at the School of Materials of Shanghai University from July 1997 to July 1999; and successively served as a human resources manager of Yanfeng Visteon Automotive Trim Systems Co., Ltd.* (延鋒偉世通汽車飾件系統有限公司) (currently renamed as Yanfeng Automotive Trim Systems Co., Ltd.* (延鋒汽車飾件系統有限公司)), Yanfeng Visteon (Beijing) Automotive Trim Systems Co., Ltd.* (延鋒偉世通(北京)汽車飾件系統有限公司) and Shanghai Yanfeng Johnson Controls Seating Co., Ltd.* (上海延鋒江森座椅有限公司) from July 1999 to March 2005; a development manager of the human resources department of Shanghai Alison (Group) Co., Ltd.* (上海埃力生(集團)有限公司) from June 2005 to April 2006; the Central China human resources manager of Schindler (China) Elevator Co. Ltd.* (迅達(中國)電梯有限公司) from July 2006 to November 2006; the senior human resources integration manager of Global Mart Limited* (購寶商業集團) from December 2006 to April 2009; and the chief human resources director of Kubao Information Technology (Shanghai) Co., Ltd.* (酷寶信息技術(上海)有限公司) from April 2009 to October 2009. Mr. Chen obtained a bachelor's degree in engineering from Shanghai University in July 1997.

Mr. Chen will not receive any remuneration from the Company for serving as a non-executive Director.

Ms. Xiaohui Guan (關曉暉), aged 54, has been a non-executive Director of the Company since December 2018 and is currently an executive director and a co-chairman of Fosun Pharma, the vice president of Fosun International and the chairman of the board of supervisors of Sinopharm. Ms. Guan joined Fosun Pharma Group in May 2000 and has been an assistant to the president, general manager of the finance department, the chief accountant, a vice president, the chief accountant and the general manager of the financial department, the senior vice president and chief financial officer, the executive president and chief financial officer of Fosun Pharma. Ms. Guan served as the executive director of Fosun Pharma since December 2021, the vice chairman of Fosun Pharma from January 2022 to April 2025, and a co-chairman of Fosun Pharma since April 2025. Ms. Guan was a non-executive director of Sinopharm and a non-executive director of Gland Pharma. In addition, Ms. Guan holds directorship, supervisorship and managerial positions in certain subsidiaries of Fosun Pharma.

Prior to joining Fosun Pharma Group, Ms. Guan worked at the Jiangxi Branch of the Industrial and Commercial Bank of China. Ms. Guan obtained a bachelor's degree in economics from Jiangxi University of Finance and Economics (江西財經大學) in the PRC in June 2000 and acquired a master's degree in professional accountancy from the Chinese University of Hong Kong in December 2007. Ms. Guan is qualified as a Chinese Certified Public Accountant and a member of the Association of Chartered Certified Accountants.

Ms. Guan will not receive any remuneration from the Company for serving as a non-executive Director.

Dr. Yi Liu (劉毅), aged 50, currently serves as an executive director and chairman of the board of directors of Sisram Medical Ltd (復鋭醫療科技有限公司) ("**Sisram Medical**", Stock Exchange stock code: 01696). Dr. Liu joined Fosun Pharma Group in November 2015 and has been the chief technology officer of the Medical Devices Division, the vice president and the senior vice president of Fosun Pharma, and has been serving as chief executive officer and president of Fosun Pharma since June 2025. In addition, Dr. Liu holds directorship and managerial positions in certain subsidiaries of Fosun Pharma.

Prior to joining Fosun Pharma Group, Dr. Liu was a trainee in Young Cadre Training Class of China National Academy of Governance (國家行政學院青年幹部培訓班) from September 1998 to July 2000; served a deputy section chief of Medical Devices Division and a section chief of Market Supervision Department of State Food and Drug Administration (now known as National Medical Products Administration) from July 2000 to August 2004; and successively served as the deputy head and head of Beijing Institute of Medical Device Testing (北京市醫療器械檢驗所) from September 2004 to November 2015.

Dr. Liu obtained a bachelor degree in engineering from Beijing Institute of Technology in July 1998, a master degree in management from Peking University in January 2006, and a doctorate degree in biomedical engineering from Beijing University of Aeronautics and Astronautics in June 2021.

Dr. Liu will not receive any remuneration from the Company for serving as a non-executive Director.

Dr. Xingli Wang, aged 62, has been a non-executive Director of the Company since August 2023. Dr. Wang joined Fosun Pharma Group in January 2023 and served as an executive president of Fosun Pharma from January 2023 to June 2025, and has been the co-president of Fosun Pharma from June 2025. In addition, Dr. Wang holds directorship in certain subsidiaries of Fosun Pharma. Prior to joining Fosun Pharma Group, from October 1992 to October 1994, Dr. Wang engaged in postdoctoral research in cardiovascular science at The University of New South Wales, Australia ("**UNSW**"). From July 1995 to December 2007, he was successively engaged in clinical residency rotation at Prince of Wales Hospital in Sydney, and served as a senior lecturer in cardiovascular medicine at UNSW and a director of cardiothoracic surgery research and tenured professor at Baylor College of Medicine, USA. From January 2008 to October 2010, he served as a medical director of Schering-Plough Corporation (New York Stock Exchange stock code: SGP) and merged into Merck & Co., Inc. in 2009). From October 2010 to May 2022, he worked in Novartis AG (New York Stock Exchange stock code: NVS), mainly serving as project director, global project clinical head, head of Novartis Global Drug R&D (China) and general manager of Biomedical Research Institute (China).

Dr. Wang obtained a bachelor's degree in medicine from Shandong Medical College (merged into Shandong University in 2000) in July 1985 and a doctorate degree in cardiovascular science from UNSW in October 1991. Dr. Wang also holds a license to practice medicine in Australia.

Dr. Wang will not receive any remuneration from the Company for serving as a non-executive Director.

Mr. Tak Young So (蘇德揚), aged 54, has been an independent non-executive Director of the Company since September 2019. Mr. So has been the founding and managing partner of FastLane Group since July 2012. Mr. So served as an independent non-executive director of Goodbaby International Holdings Limited (Stock Exchange stock code: 01086) from May 2022 to May 2025 and served as an independent non-executive director of CARsgen Therapeutics Holdings Limited (Stock Exchange stock code: 02171) from June 2021 to June 2023.

Mr. So has more than 30 years of experience in finance, accounting, investment and private equity businesses with global financial institutions and asset management companies. Mr. So served as a partner of Prospere Capital Limited from January 2018 to May 2022; the chief financial officer of Asia Pacific of asset management division for Deutsche Bank, Hong Kong from August 2007 to November 2011; the chief financial officer of PAG Capital from November 2011 to April 2012; the chief financial officer of Hamon Investment Group, an affiliate of Bank of New York Mellon from February 2005 to August 2007; the head of finance and operations of consumer banking in Hong Kong, head of asset and liability management of Greater China/Asia Pacific and chief financial officer of consumer, commercial and private bank in Hong Kong of ABN AMRO Bank N.V., Hong Kong from March 2002 to January 2005; group audit and project manager of strategic and performance improvement group in the Sydney office of Commonwealth Bank of Australia from January 1995 to January 1998; the vice president of global capital market/Asia treasury and vice president of financial controls of Bank of America, Hong Kong from January 1998 to March 2002; and began his career as an auditor with Ernst & Young, Hong Kong from February 1993 to December 1994.

Mr. So received his bachelor of business degree in accounting and finance and his master of business administration degree in banking from the University of Technology Sydney, Australia in April 1994 and September 1998, respectively. Mr. So has been a fellow member of the Certified Practising Accountants Australia (CPA Australia) since August 2011.

Mr. So is entitled to a remuneration of HK$400,000 per annum (before tax) which was determined with reference to his experience, duties and responsibilities and the prevailing market rate of companies of comparable size and similar operations.

Dr. Lik Yuen Chan (陳力元), aged 56, has been an independent non-executive Director of the Company since 2 September 2019. Dr. Chan is a world famous academic in liver diseases with extensive achievement and recognition in clinical practice and research teaching. Dr. Chan joined Union Hospital of Hong Kong in November 2020 and served as the vice president and manager of Internal Medicine Department. He served various positions in the Chinese University of Hong Kong from 2002 to 2021, including a director of the Centre of Liver Health, associate dean of external affairs of the Faculty of Medicine and a professor of the Internal Medicine Department and the Department of Medicine and Therapeutics.

Dr. Chan is a member of Royal College of Physicians of the United Kingdom since November 1995, a fellow of Hong Kong College of Physicians since May 2000, a fellow of Hong Kong Academy of Medicine since June 2000, a fellow of Royal College of Physicians of Edinburgh since July 2003, a fellow of Royal College of Physicians of London since May 2006 and a fellow of the American Association for the Study Liver Diseases since October 2016.

Dr. Chan received a bachelor's degree of medicine and surgery from the Chinese University of Hong Kong in December 1992, a doctor's degree of medicine from the Chinese University of Hong Kong in November 2001 and a master's degree in business administration from the Chinese University of Hong Kong in November 2014.

Dr. Chan is entitled to a remuneration of HK$400,000 per annum (before tax) which was determined with reference to his experience, duties and responsibilities and the prevailing market rate of companies of comparable size and similar operations.

Dr. Ruilin Song (宋瑞霖), aged 62, has been an independent non-executive Director of the Company since September 2019. Dr. Song has been a non-executive director of Luye Pharma Group Ltd.* (綠葉製藥集團有限公司) (Stock Exchange stock code: 02186) since March 2017, an independent non-executive director of Simcere Pharmaceutical Group Limited* (先聲藥業集團有限公司) (Stock Exchange stock code: 02096) since November 2019, an independent non-executive director of Jacobio Pharmaceuticals Group Co., Ltd.* (加科思藥業集團有限公司) (Stock Exchange stock code: 01167) since December 2020, and an independent non-executive director of Mediwelcome Healthcare Management & Technology Inc.* (麥迪衛康健康醫療管理科技股份有限公司) (Stock Exchange stock code: 02159) since December 2020. Dr. Song served as an independent director of Jiangxi Boya Bio-pharmaceutical Co., Ltd.* (江西博雅生物製藥股份有限公司) (Shenzhen Stock Exchange stock code: 300294) from March 2017 to March 2021, an independent director of Shanxi Zhendong Pharmaceutical Co., Ltd.* (山西振東製藥股份有限公司) (Shenzhen Stock Exchange stock code: 300158) from June 2015 to June 2021, an independent director of Tibet Aim Pharm. Inc.* (西藏易明西雅醫藥科技股份有限公司) (Shenzhen Stock Exchange stock code: 002826) from August 2015 to August 2021, and an independent director of Shenzhen Chipscreen Biosciences Co., Ltd.* (深圳微芯生物有限公司) (SSE STAR Market stock code: 688321) from May 2018 to April 2024.

During the time he worked in the Legislative Affairs Office of the State Council, Dr. Song was mainly engaged in the legislative review of Chinese medicine and health laws for 22 years. He participated in all China's medicine and health legislation activities from 1987 to 2006, in charge of the drafting and review of laws such as Drug Administration Law of the PRC, Law of the PRC on the Prevention and Treatment of Communicable Diseases and Law of the PRC on Medical Practitioners, and administrative regulations such as Regulations on Medical Institutions, Administration of Medical Devices and Emergency Regulations on Public Health Emergencies, etc. Since 2007, Dr. Song has been dedicated to the research of China's pharmaceutical policies, especially the policies for pharmaceutical innovation. Under his leadership, Research Center for Medicinal Policy of Chinese Pharmaceutical Association and PhIRDA (中國醫藥創新促進會) have finalised dozens of research projects. Dr. Song has been the executive president of PhIRDA (formerly known as China Pharmaceutical Industry Research and Development Association (中國醫藥工業科研開發促進會)) from November 2009 to September 2019, the president of PhIRDA from September 2019 to September 2020, executive president of PhIRDA from September 2020 to June 2025, and senior president of PhIRDA since June 2025. Dr. Song also served as specially-invited expert of Talent Pool Participating in and Discussing State Affairs of the CPPCC, consultant expert of Participating in and Discussing State Affairs of the Chinese Peasants and Workers Democratic Party, executive deputy director of National Drug Policy and Industrial Development Research Center of China Pharmaceutical University, visiting researcher of Shanghai Jiao Tong University, member of Advisory Committee for Traditional Chinese Medicine Strategic Decision of National Medical Products Administration, vice chairman of China Alliance of Rare Diseases (CARD), director of Chinese Pharmacist Association and a member of the Biotech Advisory Panel of the Stock Exchange among other important social positions.

Dr. Song obtained a bachelor's degree in laws from China University of Political Science and Law (中國政法大學) in June 1985, a master's degree in business administration from China Europe International Business School (中歐國際工商學院) in the PRC in November 2004 and a doctoral degree in social and administrative pharmacy from China Pharmaceutical University (中國藥科大學) in December 2018.

Dr. Song is entitled to a remuneration of HK$400,000 per annum (before tax) which was determined with reference to his experience, duties and responsibilities and the prevailing market rate of companies of comparable size and similar operations.

Mr. Yihao Zhang, aged 53. Mr. Zhang served as the global executive vice president of GE Healthcare, president and CEO of GE Healthcare China from July 2019 to July 2025, fully responsible for the strategy formulation, implementation, and operation of GE Healthcare in the Chinese market. Mr. Zhang successively held various positions at Danaher Corporation and its subsidiaries from March 2003 to June 2019, including China deputy general manager, general manager, vice president and general manager of Greater China, president of the Dental Products Business Platform for Greater China and Asia Pacific region, and senior vice president. Mr. Zhang served as the brand manager at P&G from May 2002 to August 2002; the financial analysis manager at TRW in the United States from July 1996 to May 2001.

Mr. Zhang previously served as the vice chairman of the Advanced Medical Technology Association in China, and was awarded the Shanghai "Magnolia Silver Award" in September 2021. Mr. Zhang received a bachelor's degree in mathematics and economics from Ohio Wesleyan University in the United States in 1996, and a master's degree in business administration from Kellogg School of Management at Northwestern University in the United States and a master's degree in engineering management from the McCormick School of Engineering at Northwestern University in the United States in 2003, respectively.

Mr. Zhang is entitled to a remuneration of HK$400,000 per annum (before tax) which was determined with reference to his experience, duties and responsibilities and the prevailing market rate of companies of comparable size and similar operations.

If the above candidates are appointed as Directors, they shall hold their office until the expiry of the term of the fourth session of the Board in accordance with their respective service contracts with the Company. The remuneration of the Directors of the fourth session of the Board is determined in accordance with the relevant regulations and mechanisms.

As at the date of this announcement, save as disclosed above, the Director candidates had confirmed that they (i) did not hold any directorships or supervisor positions in other publicly listed companies in the last three years nor take up any posts in any group members of the Company; (ii) did not have any relationship with any Directors, Supervisors, senior management, substantial Shareholders or controlling Shareholders of the Company; and (iii) did not have any interests in the Shares or underlying Shares of the Company and its associated corporations within the meaning of Part XV of SFO.

Each of the candidates for independent non-executive Directors has confirmed that (i) he has complied with various factors relating to independence as set out in Rules 3.13 (1) to (8) of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence as at the date of this announcement.

Save as disclosed above, there is no other matter relating to the proposed appointment of Directors that needs to be brought to the attention of the Shareholders, nor is there any other information to be disclosed pursuant to any of the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules.

The biographical details of the candidates for Shareholder representative supervisors are set out as below:

Ms. Rongli Feng (馮蓉麗), aged 49, has been a Supervisor of the Company and the chairman of the Board of Supervisors since May 2020 and currently serves as an executive president of Fosun Pharma, a non-executive director of Sinopharm and a non-executive director of Sisram Medical. Ms. Feng joined Fosun Pharma in April 2020 and served as the vice president of Fosun Pharma from April 2020 to March 2021, she has been the senior vice president of Fosun Pharma from March 2021 to January 2024, and she has been the executive president of Fosun Pharma since January 2024. Moreover, Ms. Feng holds directorship in certain subsidiaries of Fosun Pharma. Prior to joining Fosun Pharma Group, Ms. Feng served as a human resources supervisor of Sealed Air Packaging (Shanghai) Co., Ltd.* (希悦爾包裝(上海)有限公司) from July 1996 to April 2000, a human resources manager of Grundfos Pumps (Shanghai) Co., Ltd.* (格蘭富水泵(上海)有限公司) from April 2000 to November 2002, the Asia-Pacific human resources manager of Emerson Electric (China) Holdings Co., Ltd.* (艾默生電氣(中國)投資有限公司) from November 2002 to July 2006, the China human resources planning manager of Dow Chemical (China) Co., Ltd.* (陶氏化學(中國)有限公司) from August 2006 to November 2009, the director of human resources of Shanghai Roche Pharmaceutical Co., Ltd.* (上海羅氏製藥有限公司) from November 2009 to January 2015, and the senior director of human resources at F. Hoffmann-La Roche AG from February 2015 to July 2018. Ms. Feng served as the deputy chief human resources officer of Shanghai Fosun High Technology (Group) Co., Ltd.* (上海復星高科技(集團)有限公司) and the managing director of the human resources of Shanghai Fosun Venture Capital Investment Management Co., Ltd.* (上海復星創業投資管理有限公司) from July 2018 to April 2020. Ms. Feng graduated from Shanghai University (上海大學) in the PRC with a major in microcomputer application in July 1996. In February 2002, she obtained a master's degree in business administration from Columbia Southern University.

Ms. Feng will not receive any remuneration from the Company for serving as a Shareholder representative Supervisor.

Mr. Deli Kong (孔德力), aged 51, has been a Supervisor of the Company since August 2016. Mr. Kong joined Fosun Pharma Group in June 2005 and worked at Fosun Pharma from June 2005 to December 2012, with his last position as a patent affairs senior officer. Mr. Kong has been working with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.* (上海復星醫藥產業發展有限公司) since January 2013 and successively served as the senior researcher, deputy director, assistant to head of research institute and minister of policy and information research centre, deputy head of the research institute and minister of policy and information research centre, assistant to the president, the vice president and general manager of the patent affairs department, and the executive vice president of the global R&D centre. Prior to joining Fosun Pharma Group, Mr. Kong also previously served as an assistant researcher at the Shanghai Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences* (中國科學院上海生物化學與細胞生物研究所). Mr. Kong obtained a master's degree in biochemical engineering from the School of Engineering of East China University of Science and Technology (華東理工大學) in the PRC in July 1999.

Mr. Kong will not receive any remuneration from the Company for serving as a Shareholder representative Supervisor.

If the above candidates are appointed as Shareholder representative Supervisors, they shall hold their office until the expiry of the term of the fourth session of the Board of Supervisors according to their respective service contracts with the Company.

As at the date of this announcement, save as disclosed above, the Shareholder representative Supervisor candidates had confirmed that they (i) did not hold any directorships or supervisor positions in other publicly listed companies in the last three years nor take up any posts in any group members of the Company; (ii) did not have any relationship with any Directors, Supervisors, senior management, substantial Shareholders or controlling Shareholders of the Company; and (iii) did not have any interests in the Shares or underlying Shares of the Company and its associated corporations within the meaning of Part XV of SFO.

Save as disclosed above, there is no other matter relating to the proposed appointment of shareholder representative Supervisors that needs to be brought to the attention of the Shareholders, nor is there any other information to be disclosed pursuant to any of the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules.

The biographical details of the employee representative Supervisor are set out below:

Mr. Zhiyong Liu (劉志勇), aged 52, served as a Supervisor of the Company and a supervisor of Henlius Biopharmaceutical and Shanghai Henlius Bioscience Co., Ltd.* (上海復宏瑞霖生物技術有限公司), which are the subsidiaries of the Company, since January 2025. Mr. Liu joined the Group in June 2020, and currently serves as the general manager of production. Prior to joining the Group, Mr. Liu successively served as director of preparation workshop, manager of the planning department, and manager of the engineering department of Changchun GeneScience Pharmaceutical Limited* (長春金賽藥業股份有限公司) (currently known as Changchun GeneScience Pharmaceutical Co., Ltd.* (長春金賽藥業有限責任公司)) from 1997 to 2012. From March 2012 to June 2017, he served as the production director at Jilin Qijian Bio-Pharmaceutical Co., Ltd.* (吉林省奇健生物技術有限公司). From July 2017 to January 2019, he served as the production director at Genovate (Changzhou) Biotechnology Co., Ltd* (健亞(常州)生物技術有限公司). From April 2019 to May 2020, he served as an assistant to the president and executive deputy general manager of Zhejiang Huajinyike Biopharmaceutical Co., Ltd.* (浙江華津依科生物製藥有限責任公司). Mr. Liu obtained a bachelor's degree in physical chemistry from Jilin University (吉林大學) in July 1997 and a master's degree in bioengineering from Jilin University in June 2016.

Mr. Liu has entered into a letter of appointment with the Company. Mr. Liu will not receive additional remuneration from the Company for serving as an employee representative Supervisor of the Company.

As at the date of this announcement, save as disclosed above, Mr. Liu has confirmed that he (i) did not hold any directorships or supervisor positions in other publicly listed companies in the last three years nor take up any posts in any group members of the Company; (ii) did not have any relationship with any Directors, Supervisors, senior management, substantial Shareholders or controlling Shareholders of the Company; and (iii) did not have any interests in the Shares or underlying Shares of the Company and its associated corporations within the meaning of Part XV of SFO.

Save as disclosed above, there is no other matter in respect of the re-appointment of Mr. Liu that needs to be brought to the attention of the Shareholders, nor is there any other information relating to Mr. Liu that needs to be disclosed pursuant to any of the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules.

* *For identification only*